Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132014 · ClinicalTrials.gov registry record · Early Phase 1
Autologous OC-DC Vaccine in Ovarian Cancer
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 67
- Enrollment target
NCT01132014 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 67 participants.
The verdict
NCT01132014, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a Five cohort sequential clinical trial for subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-DC, an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with intravenous Bevacizumab and cyclophosphamide or in combination with intravenous Bevacizumab, cyclophosphamide and aspirin. Study duration is 24 months.
Interventions
- BIOLOGICAL OCDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-05 |
| Est. Completion | 2018-05-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01132014
The ClinicalTrials.gov registry entry for NCT01132014 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OCDC is the first listed.
NCT01132014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01132014 about?
NCT01132014 is a clinical study titled "Autologous OC-DC Vaccine in Ovarian Cancer". This is a Five cohort sequential clinical trial for subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-DC, an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate...
What is the current status of trial NCT01132014?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 67 participants. The study started on 2010-05. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT01132014?
The interventions under investigation include: OCDC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01132014?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.